跳至主要内容
临床试验/NCT02249923
NCT02249923招募中不适用

Pediatric Pulmonary Hypertension Network (PPHNet) Informatics Registry

New York Medical College14 个研究点 分布在 2 个国家目标入组 2,500 人开始时间: 2014年10月最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
入组人数
2,500
试验地点
14
主要终点
Time to clinical worsening

研究概览

简要总结

Patients are being asked to be in this research study because medical researchers hope that by gathering information about a large number of children with pulmonary hypertension over time, their understanding of the disease process will increase and lead to better treatment. Investigators believe that pulmonary hypertension in children is different than pulmonary hypertension in adults and this study will help us understand those differences.

详细描述

Pulmonary Hypertension (PH) is a syndrome characterized by vasoconstriction and abnormal growth and function of endothelial and smooth muscle cells and other components within the pulmonary vessels, which leads to elevation of the pulmonary artery pressure. PH may be idiopathic (primary) without any known cause. Some cases of PH are familial. PH may also be secondary to a specific disease process such as portal hypertension, congenital heart disease, chronic lung disease, thromboembolic disease, connective tissue disease, human immunodeficiency virus (HIV), and use of anorexigens. Left untreated, PH is often progressive and fatal. There is no cure for PH. Therapy focuses upon treatment of secondary causes if present, and reduction of the pulmonary artery pressure through medical therapy. There have been many new developments within the past few years in the management of patients with PH. While there is no cure for PH early detection and treatment are important for survival of patients. Limited data is available that describes the etiologies, clinical course and prognosis of pediatric pulmonary hypertension.

Objectives

Aim 1: Clinical Research

  1. To provide a mechanism to store information about newborns, infants and children with PH;
  2. To determine the incidence and natural history of the various etiologies of pediatric PH;
  3. To define the investigator current diagnostic and therapeutic approaches to the diverse conditions associated with pediatric PH;
  4. To determine the response of children with PH to chronic therapies.

Aim 2: Research Infrastructure To create a robust scalable data architecture, to combine traditional registry data, electronic Health Record (EHR), and PRO (Patient Reported Outcome) data in a single resource.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
1 Day 至 21 Years(Child, Adult)
性别
All
接受健康志愿者

入选标准

  • The subject's age of onset of pulmonary hypertension must be prior to age 18 years
  • The person providing consent must be able to read either Spanish or English.
  • The subject (and/or parent/legal guardian) must be able to provide informed consent

排除标准

  • Diagnosed with pulmonary hypertension after age 18
  • Refusal to sign informed consent

结局指标

主要结局

Time to clinical worsening

时间窗: 12 months

Time to clinical worsening for death, cardiac transplant, atrial septostomy, or Potts shunt.

次要结局

  • Escalation of Pulmonary Hypertension Therapy(36 months)
  • Right Heart Failure(36 months)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (14)

Loading locations...

相似试验